STELARA® Resources

  Resources for Your Patient
PDF

Enroll in the STELARA withMe Program (Downloadable Form)

Download the enrollment form for your patients to enroll.

Click out icon

Enroll in the STELARA withMe Program (Electronic Form)

Online STELARA withMe enrollment form for patients to fill out.

  Resources for Your Practice
Click out icon

Janssen CarePath Provider Portal

The Janssen CarePath Provider Portal gives you 24-hour online access to request and review benefits investigations, request prior authorization support and status monitoring, enroll eligible patients in the STELARA withMe Savings Program, and view Savings Program transactions as requested by the patient.

PDF

Dosing and Administration Guide

A guide containing details on how to prepare and administer STELARA® for both intravenous (IV) infusion and subcutaneous (subQ) maintenance dosing.

PDF

About STELARA withMe

An overview of our support program.

PDF

Where to Purchase the IV Dose

Download a list of specialty distributors authorized to sell STELARA®.

PDF

Benefits Investigation and Prescription Form

Filling out the Benefits Investigation and Prescription Form eliminates the need to write 2 prescriptions and perform 2 separate benefits investigations.

American Gastroenterological Association (AGA) Strong Recommendation seal

STELARA® RECEIVES A STRONG RECOMMENDATION* FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION (AGA)1

STRONG RECOMMENDATIONS* FOR STELARA® FROM THE AGA GUIDELINES ON THE MANAGEMENT OF MODERATE TO SEVERE CD:

In adult outpatients with moderate to severe Crohn's disease (CD) who are naïve to biologic drugs, the use of ustekinumab, infliximab, or adalimumab are recommended over certolizumab pegol for the induction of remission (moderate certainty of evidence*).

These recommendations were developed by the AGA, independent of Janssen

  • Please see Important Safety Information, and full Prescribing Information, including Boxed Warning for Remicade® (infliximab).

*The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to evaluate the level of evidence and strength of recommendations. The level of evidence could range from “high” (very confident that the true effect lies close to the estimate of the effect), “moderate” (moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different), “low” (confidence in the estimate is limited; the true effect may be substantially different from the estimate of effect), or “very low” (very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect). “The AGA recommends…” was used for “strong” recommendations (most individuals should receive the recommended course of action; formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences). “The AGA suggests” was used for “conditional” recommendations (different choices would be appropriate for different patients; decision aids may be useful in helping individuals in making decisions consistent with their values and preferences; clinicians should expect to spend more time with patients when working towards a decision).

Reference: 1. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2496-2508.